Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICRA: Paclitaxel + Tremelimumab +/- Durvalumab in Urothelial Cancer
NCT03871036Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2019
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tiragolumab in urothelial carcinoma (UC), sponsored by Netherlands Cancer Institute. Started May 2019; status: completed.
02
Drugs
tiragolumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03871036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871036.